A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
January 8, 2026 6:33 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
Backed by Menlo Ventures, BrainGrid tackles planning gaps as AI makes software building accessible to more founders.
Updated
April 1, 2026 8:37 AM
A phone screen with app icons. PHOTO: UNPSLASH
As artificial intelligence makes it easier to write code, a different problem is starting to surface. Building software is no longer limited by technical skill alone. Increasingly, the challenge lies in deciding what to build, how to structure it, and how to turn an idea into something that actually works.
That shift sits at the centre of BrainGrid, a startup that has raised $1 million in pre-seed funding led by Menlo Ventures, with participation from Next Tier Ventures and Brainstorm Ventures. The company is building what it describes as an AI-powered planning layer for people who want to create software but may not have a technical background.
The timing reflects a broader change in how products are being built. Tools like Claude Code and Cursor have made it possible to generate working code through simple prompts. For many first-time founders, this has lowered the barrier to entry. But writing code is only one part of the process. Turning that code into a reliable product requires structure, sequencing and clarity—areas where many projects begin to fall apart.
In traditional teams, this responsibility sits with product managers who define what needs to be built and in what order. Without that layer, even well-written code can lead to products that feel disjointed or incomplete. Features may not work together, integrations can break and the final product often does not match the original idea.
BrainGrid is designed to address that gap. Instead of focusing on generating code, it helps users map out the structure of a product before development begins. The aim is to give builders a clearer starting point so that the tools they use—whether human or AI—can produce more consistent results.
The company says more than 500 builders have already used it to create software products across areas like fitness, healthcare and productivity. These range from first-time founders experimenting with new ideas to experienced developers working independently. In many cases, the products are already live and generating revenue, suggesting that the demand is not just for experimentation but for building something that can scale.
For investors, the appeal lies in the evolving role of software development. As AI takes on more of the technical work, the value shifts toward defining the problem and structuring the solution. In that sense, planning becomes less of a background task and more of a core capability.
The US$1 million raise is relatively modest, but it points to a larger trend. As more people gain access to AI tools, the number of potential builders expands. What remains limited is the ability to organise ideas into products that work in the real world. If that shift continues, the next wave of software may not be defined by who can code, but by who can plan.